Aventis Pasteur S.A.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Aventis Pasteur S.A..The latest application filed is for "intranasal delivery of pneumococcal polysaccharide vaccines".
- Aventis Pasteur S.A. - Lyon FR
- Aventis Pasteur SA - Lyons Cedex FR
- Aventis Pasteur SA - Lyons FR
- Aventis Pasteur, S.A. - Lyons FR
- Aventis Pasteur SA -
- Aventis Pasteur, S.A. - Lyon Cedex FR
- Aventis Pasteur S.A. - Lyons Cedex FR
- Aventis Pasteur S.A. - FR FR
| Patent | Date |
|---|---|
| Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide Grant 7,812,006 - Mistretta , et al. October 12, 2 | 2010-10-12 |
| Vaccine composition Grant 7,767,658 - Haensler August 3, 2 | 2010-08-03 |
| Multivalent vaccine composition having increased stability of capsular polysaccharide Grant 7,404,960 - Francon July 29, 2 | 2008-07-29 |
| Assaying the teichoic acids of gram.sup.+ bacteria Grant 7,320,874 - Talaga , et al. January 22, 2 | 2008-01-22 |
| Method and apparatus for sterile connection between two flexible tubes Grant 7,122,094 - Baradon , et al. October 17, 2 | 2006-10-17 |
| Intranasal delivery of pneumococcal polysaccharide vaccines App 20060140981 - Jonsdottir; Ingileif | 2006-06-29 |
| Methods for inducing HIV-neutralizing antibodies Grant 7,056,519 - Boudet , et al. June 6, 2 | 2006-06-06 |
| Vaccine composition and stabilization method using high molecular weight PVP Grant 6,982,088 - Francon , et al. January 3, 2 | 2006-01-03 |
| Vaccine composition App 20050208060 - Haensler, Jean | 2005-09-22 |
| Pharmaceutical composition for immunization against AIDS App 20050118188 - Dalenccon, Francois ; et al. | 2005-06-02 |
| Polypeptide inducing antibodies neutralizing HIV Grant 6,861,253 - Brasseur , et al. March 1, 2 | 2005-03-01 |
| Assaying the teichoic acids of gram+ bacteria App 20050009121 - Talaga, Philippe ; et al. | 2005-01-13 |
| Adjuvant for vaccine composition App 20050002952 - Haensler, Jean ; et al. | 2005-01-06 |
| GP41 antigen Grant 6,821,723 - Chevalier , et al. November 23, 2 | 2004-11-23 |
| Vaccine composition comprising iron phosphate as vaccine adjuvant App 20040228880 - Sauzeat, Elisabeth | 2004-11-18 |
| Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide App 20040170638 - Mistretta, Noelle ; et al. | 2004-09-02 |
| Adjuvant for a vaccine composition Grant 6,780,421 - Haensler , et al. August 24, 2 | 2004-08-24 |
| Trimer of HIV env gene expression product Grant 6,737,067 - Chevalier May 18, 2 | 2004-05-18 |
| Method and device for cell lysis Grant 6,664,049 - Chevalier December 16, 2 | 2003-12-16 |
| Use of poxviruses as enhancer of specific immunity Grant 6,641,816 - Chevalier , et al. November 4, 2 | 2003-11-04 |
| Immunostimulant emulsion Grant 6,610,308 - Haensler August 26, 2 | 2003-08-26 |
| Method for the reductive amination of polysaccharides Grant 6,596,861 - Moreau July 22, 2 | 2003-07-22 |
| Polysaccharide-peptide-conjugates Grant 6,472,506 - Moreau , et al. October 29, 2 | 2002-10-29 |
| Use of an amphipathic compound for providing an adjuvant to a subunit vaccine Grant 6,472,159 - Darbouret , et al. October 29, 2 | 2002-10-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 